Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

the SafeHer Study Group

Research output: Contribution to journal › Article › peer-review

41 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients'. Together they form a unique fingerprint.

Agricultural and Biological Sciences

Pharmacology, Toxicology and Pharmaceutical Science

Medicine and Dentistry